SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

J I Chacón López-Muñiz,M Bellet Ezquerra,S López-Tarruella Cobo,L De La Cruz Merino,S Antolin Novoa,E Martínez Dueñas,J Gavilá Gregori,M Oliveira,M A Seguí Palmer,I Álvarez López

doi:10.1007/s12094-018-02010-w

Abstract

Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference.

Highlights

Breast cancer (BC) represents the first cause of invasive cancer in the Spanish women, accounting for 29% of all female cancers
The SEOM guidelines have been developed with the consensus of ten breast cancer oncologists from the cooperative groups GEICAM (Spanish Breast Cancer Research Group) and SOLTI (Spanish Collaborative Group for the Study, treatment and other experimental strategies in solid tumors)
To assign a level of certainty (LC) and a grade of recommendation (GR) to the different statements described in the clinical guidelines, the United States Preventive Services Task Force (USPSTF) guidelines methodology was selected as reference, as the previously adopted for the former version of SEOM recommendations [4] (Table 1)

Summary

Introduction

Breast cancer (BC) represents the first cause of invasive cancer in the Spanish women, accounting for 29% of all female cancers. 26,730 new cases and 6477 deaths are estimated annually in Spain [1]. Metastatic BC (MBC) remains virtually an incurable disease, with reported median overall survival (OS) of approximately 2 years. Improved OS (up to 5 years) has been observed recently for certain subtypes, in HER2-positive disease. De novo metastatic disease has better 5-year OS that recurrent MBC and prognosis appear to improve over time [2]. Patients with loco-regional recurrence (LRBC) may or may not be amenable to radical local treatment. Overall, according to a Spanish study, an increase in OS has been observed in the recent years in LRBC patients [3]

Methodology

Findings

Compliance with ethical standards